CTOs on the Move

Cary Pharmaceuticals Inc

www.carypharma.com

 
Cary Pharmaceuticals Inc is a Great Falls, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 1K-5K
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Edge Mechanical Systems

Edge Mechanical Systems is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BrainStorm Cell

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to over 50 patients with ALS in clinical trials conducted in Israel and the United States, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States.

Alnara Pharmaceuticals

Alnara Pharmaceuticals, Inc. is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zydus Pharmaceuticals (USA)

Zydus Pharmaceuticals (USA) is a Pennington, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

XTuit

XTuit Pharmaceuticals, Inc. is a biopharmaceutical company developing novel microenvironment-activated therapeutics targeting key mechanisms resulting in hypoxia, decreased drug uptake, drug resistance, and decreased immune response. The Company’s proprietary drug development pipeline and integrated, sophisticated clinical biomarker platform will be used for accelerated clinical development across selected cancers and fibrotic disorders. XTuit’s compounds act through pleiotropic mechanisms to inhibit extracellular matrix synthesis and stabilization, and to silence activated stromal cells, including cancer-associated fibroblasts and stellate cells. As a result, XTuit compounds alleviate hypoxia and enable enhanced drug uptake through solid stress reduction. Moreover, the drugs have been shown to down-regulate stroma-induced tumor and inflammation signaling pathways to overcome treatment resistance. XTuit’s first two lead series are being developed for early clinical proof-of-concept in liver diseases and cancer.